GSK’s hepatitis B drug touts functional curative potential in double Phase III win

Analysts are heralding bepirovirsen as a potentially strong future growth driver for GSK and its infectious disease portfolio. Analysts are heralding bepirovirsen as a potentially strong future growth driver for GSK and its infectious disease portfolio. Some analysts say that bepirovirsen could have transformative potential on the CHB market, if approved. Credit: Keronn art / Shutterstock.com. GSK and Ionis Pharmaceuticals’ genetic medicine, bepirovirsen, has demonstrated its functional curative potential in chronic hepatitis B (CHB) – a development that analysts say could see the drug become a potential disruptor in the condition. According to pooled data from the Phase III B-Well…

Source: Clinical Trials Arena